These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1059 related items for PubMed ID: 15073491

  • 1. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P, Rossing K, Parving HH.
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [Abstract] [Full Text] [Related]

  • 2. The end of the road for dual renin-angiotensin system blockade in diabetic nephropathy: which way now?
    Advani A.
    Can J Diabetes; 2014 Oct; 38(5):292-5. PubMed ID: 25172268
    [No Abstract] [Full Text] [Related]

  • 3. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 4. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ.
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [Abstract] [Full Text] [Related]

  • 5. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease.
    Andersen NH, Mogensen CE.
    Curr Hypertens Rep; 2004 Oct; 6(5):369-76. PubMed ID: 15341690
    [Abstract] [Full Text] [Related]

  • 6. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
    Yamout H, Lazich I, Bakris GL.
    Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

  • 8. Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Jacobsen P, Parving HH.
    Kidney Int Suppl; 2004 Nov; (92):S108-10. PubMed ID: 15485400
    [Abstract] [Full Text] [Related]

  • 9. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Nov; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [Abstract] [Full Text] [Related]

  • 11. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 12. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P, Andersen S, Jensen BR, Parving HH.
    J Am Soc Nephrol; 2003 Apr 09; 14(4):992-9. PubMed ID: 12660333
    [Abstract] [Full Text] [Related]

  • 13. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Apr 09; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 14. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 09; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 15. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb 09; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 16. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH, Fu P.
    Chin Med J (Engl); 2016 Jan 05; 129(1):81-7. PubMed ID: 26712437
    [Abstract] [Full Text] [Related]

  • 17. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K, Christensen PK, Jensen BR, Parving HH.
    Diabetes Care; 2002 Jan 05; 25(1):95-100. PubMed ID: 11772908
    [Abstract] [Full Text] [Related]

  • 18. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG.
    J Manag Care Pharm; 2004 Sep 05; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [Abstract] [Full Text] [Related]

  • 19. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M, Simioni N, Masiero A.
    Int Urol Nephrol; 2009 Sep 05; 41(1):119-26. PubMed ID: 18958580
    [Abstract] [Full Text] [Related]

  • 20. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 05; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.